Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: A double-tracer study

Diabetes Care

Volumn 36, Issue 9, 2013, Pages 2756-2762

  Solis Herrera, Carolina ^a   Triplitt, Curtis ^a   De Jesús Garduno Garcia, Jose ^a   Adams, John ^a   Defronzo, Ralph A ^a   Cersosimo, Eugenio ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; SITAGLIPTIN;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG POTENTIATION; DRUG TOLERABILITY; FEMALE; FOOD INTAKE; GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FASTING; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; PYRAZINES; TRIAZOLES;

EID: 84891784779     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-2072     Document Type: Article

References (26)

1. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29: 2632-2637
2. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007; 30: 1979-1987
3. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, noninferiority trial. Diabetes Obes Metab 2007;9: 194-205
4. Deacon CF. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 2004;53: 2181-2189
5. Ahrén B. Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties. Expert Opin Investig Drugs 2006;15: 431-442
6. Balas B, Baig MR, Watson C, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007;92: 1249-1255
7. Steele R, Bjerknes C, Rathgeb I, Altszuler N. Glucose uptake and production during the oral glucose tolerance test. Diabetes 1968;17: 415-421
8. Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001;24: 489-494
9. Lindsay JR, Duffy NA, McKillop AM, et al. Inhibition of dipeptidyl peptidase IV activity by oral metformin in type 2 diabetes. Diabet Med 2005;22: 654-657
10. Green BD, Irwin N, Duffy NA, Gault VA, O'harte FP, Flatt PR. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur J Pharmacol 2006;547: 192-199
11. Mannucci E, Pala L, Ciani S, et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 2005;48: 1168-1172
12. Fadini GP, Albiero M, Menegazzo L, de Kreutzenberg SV, Avogaro A. The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients. Diabetes Obes Metab 2012;14: 518-522
13. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992;41: 368-377
14. Hovorka R, Soons PA, Young MA. ISEC: a program to calculate insulin secretion. Comput Methods Programs Biomed 1996; 50: 253-264
15. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22: 1462-1470
16. Jackson RA, Roshania RD, Hawa MI, Sim BM, DiSilvio L. Impact of glucose ingestion on hepatic and peripheral glucose metabolism in man: an analysis based on simultaneous use of the forearm and double isotope techniques. J Clin Endocrinol Metab 1986;63: 541-549
17. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132: 2131-2157
18. Carr RD, Larsen MO, Jelic K, et al. Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men. J Clin Endocrinol Metab 2010;95: 872-878
19. Cervera A, Wajcberg E, Sriwijitkamol A, et al. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 2008;294:E846-E852
20. Cersosimo E, Gastaldelli A, Cervera A, et al. Effect of exenatide on splanchnic and peripheral glucose metabolism in Type 2 Diabetic Subjects. J Clin Endocrinol Metab 2011;96: 1763-1770
21. Mudaliar S, Henry RR. The incretin hormones: from scientific discovery to practical therapeutics. Diabetologia 2012;55: 1865-1868
22. Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactatemetabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996;81: 4059-4067
23. Hirshman MF, Goodyear LJ, Braun B, et al. Combining short-term metformin treatment and one bout of exercise does not increase insulin action in insulin-resistant individuals.AmJ Physiol EndocrinolMetab 2010;298:E815-E823
24. Mentis N, Vardarli I, Köthe LD, et al. GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes. Diabetes 2011;60: 1270-1276
25. Deacon CF, Nauck MA, Meier J, Hücking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000;85: 3575-3581
26. Lenhard JM, Croom DK, Minnick DT. Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. Biochem Biophys Res Commun 2004;324: 92-97